What is Imprimis Pharmaceuticals?
Imprimis Pharmaceuticals is dedicated to enhancing patient health and quality of life through the development and commercialization of compounded drug formulations. A core element of its strategy involves leveraging Accudel, a patented topical drug delivery platform. This innovative approach aims to provide highly targeted, site-specific treatments, thereby reducing the systemic side effects often associated with traditional drug delivery methods like oral medications. The company's focus on compounded formulations and topical delivery positions it as a key player in advancing patient-centric pharmaceutical solutions.
How much funding has Imprimis Pharmaceuticals raised?
Imprimis Pharmaceuticals has raised a total of $48.8M across 4 funding rounds:
Share Placement
$8M
Other Financing Round
$15M
Share Placement
$9.8M
Debt
$16M
Share Placement (2012): $8M with participation from Undisclosed
Other Financing Round (2015): $15M led by Life Sciences Alternative Funding
Share Placement (2016): $9.8M, investors not publicly disclosed
Debt (2017): $16M featuring SWK Funding LLC
Key Investors in Imprimis Pharmaceuticals
Life Sciences Alternative Funding
Life Sciences Alternative Funding is a financial entity specializing in the life sciences sector, likely providing alternative financing solutions to companies in the pharmaceutical and biotechnology industries.
SWK Funding LLC
SWK Funding LLC is identified as a debt provider, indicating a role in financing the company's operations through credit facilities.
Undisclosed Investors
What's next for Imprimis Pharmaceuticals?
With substantial enterprise-level backing and a recent strategic investment, Imprimis Pharmaceuticals is poised for significant growth and expansion. The company's focus on its proprietary Accudel topical drug delivery platform, coupled with its mission to improve patient outcomes, suggests a strategic direction towards scaling its operations and potentially exploring new therapeutic areas. Future endeavors will likely involve further clinical validation, market penetration, and strategic partnerships to maximize the impact of its innovative drug formulations.
See full Imprimis Pharmaceuticals company page
